Latest News

According to the company, the FDA’s decision was supported by visual function results from the phase 2 ACUITY trial in ON.

The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026.

A recent study reveals significant ocular complications from monkeypox, highlighting the need for enhanced eye health strategies in affected regions.

A recent study represents a step forward in investigations of the retinal layers as they are affected by glaucoma.

Jennifer E. Thorne, MD, PhD, discusses evidence from the ADJUST trial, including relapse risk, retreatment success, and how clinicians should monitor children when considering adalimumab discontinuation.

The company can now initiate its phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy.

Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, while noting concerns around data reliability, patient adherence, and reimbursement.

The letter noted the FDA is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD, according to the company.

Concentric lens positioning of an adjustable lens helps avoid a late myopic shift.

Daniela Ferrara, MD, discusses how data from low- and middle-income countries can strengthen US trials, improve equity, and inform innovation as the field looks toward 2026.

An in-depth look at the FDA approvals and clinical milestones that defined 2025 and how they are poised to influence practice patterns moving into 2026.

The year introduced shifts in residency education, and program directors reflect on changes, challenges, and what’s next.